Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $509 | $249 | $204 | $180 |
| % Growth | 104% | 22.2% | 13.3% | – |
| Cost of Goods Sold | $20 | $13 | $18 | $18 |
| Gross Profit | $489 | $237 | $186 | $162 |
| % Margin | 96% | 94.9% | 91.3% | 90% |
| R&D Expenses | $341 | $428 | $477 | $601 |
| G&A Expenses | $263 | $278 | $219 | $182 |
| SG&A Expenses | $359 | $295 | $237 | $195 |
| Sales & Mktg Exp. | $97 | $17 | $18 | $14 |
| Other Operating Expenses | $0 | $0 | $9 | $8 |
| Operating Expenses | $701 | $723 | $724 | $804 |
| Operating Income | -$212 | -$486 | -$549 | -$648 |
| % Margin | -41.7% | -195% | -269.2% | -360.1% |
| Other Income/Exp. Net | $146 | -$20 | -$15 | $1 |
| Pre-Tax Income | -$66 | -$506 | -$552 | -$641 |
| Tax Expense | $1 | $1 | $5 | $3 |
| Net Income | -$67 | -$507 | -$558 | -$644 |
| % Margin | -13.2% | -203.3% | -273.2% | -357.7% |
| EPS | -1.07 | -8.37 | -9.35 | -11.01 |
| % Growth | 87.2% | 10.5% | 15.1% | – |
| EPS Diluted | -1.07 | -8.37 | -9.35 | -11.01 |
| Weighted Avg Shares Out | 63 | 61 | 60 | 59 |
| Weighted Avg Shares Out Dil | 63 | 61 | 60 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $41 | $33 | $0 | $2 |
| Interest Expense | $69 | $52 | $17 | $0 |
| Depreciation & Amortization | $16 | $12 | $20 | $13 |
| EBITDA | $19 | -$470 | -$515 | -$628 |
| % Margin | 3.8% | -188.6% | -252.6% | -348.9% |